Role of Vitamin D Levels (Serum 25-hydroxyvitamin D) and Cognitive Impairment in the Occurrence of Falls
NCT ID: NCT02517164
Last Updated: 2015-08-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Many data suggest that cognitive, common disorders in the elderly, is a major risk factor for falls and the elderly often have difficulty managing their parallel postural stability and other situations requiring attentional resources. Furthermore, the data used to evoke a role of vitamin D in the risk of falls in the elderly. Indeed, vitamin D has beneficial effects on muscle and on the human brain and several recent studies have shown the existence of positive relationship between serum 25 hydroxyvitamin D and cognitive function. These different actions may explain the beneficial effect of vitamin D supplementation on the risk of falling for practicing daily oral doses of vitamin D in the range of 700-1000 IU.
Our goal in this study is to confirm the existence of a link between vitamin D status and some areas of cognitive functions, and analyze the roles played by vitamin D deficiency and cognitive impairment in the occurrence of falls. The study will also seek the existence of a threshold level of 25-hydroxyvitamin D below which may arise cognitive disorders. The prospective follow-up of patients for 2 years will study the effect of correcting the vitamin D deficiency (initial correction and regular supplementation) on cognitive function, balance, walking and the occurrence of falls.
The study will be conducted in 150 subjects aged 50 years and over and fell in 150 subjects aged 50 and over at risk of falling. These patients will be enrolled in the Emergency Services, Orthopedics, Geriatrics, and Rheumatology of the University Hospital of Caen. All subjects will receive a dose of 25 hydroxyvitamin D, a comprehensive study of cognitive function, tests of balance and walking and assessment of activities of daily living and depression. All the examinations and tests will be carried out during the same half day. According to current recommendations, it will be prescribed a treatment with Vitamin D to subjects with a lowered rate of 25 hydroxyvitamin D (\<30 ng / ml) to normalize the rate and will be advised doctors to prescribe regular supplementation vitamin D in order to maintain it in the standard rate (30 to 80 ng / ml). The effect of the correction of hypovitaminosis D, confirmed by controlling the rate of 25 hydroxyvitamin D, on cognitive functions, balance and walking will be analyzed 3 months and 9 months. During the two years following their inclusion in the study, subjects will be contacted by a phone call every 3 months during which will be recorded any falls they have been victims, as well as changes to their drug treatments, particularly case of regular intake of vitamin D supplementation.
If our hypothesis were true, it would be appropriate to consider a new approach to prevention of fractures involving the correction of vitamin D deficiency, cognitive rehabilitation and cognitive-motor drive in subjects with cognitive impairment.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint
NCT02185222
Serum, Dietary and Supplemental Vitamin D's Association With Cognitive Decline
NCT03320109
Study To Understand Fall Reduction and Vitamin D in You
NCT02166333
Vitamin D as a Supplement Against Falls in Elderly Study
NCT01827345
Vitamin D Supplementation in Postmenopausal Women With Osteoporosis: Proposal of a Therapeutic Regimen in Practice
NCT02518763
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Fallers
patients aged 50 years and over who already fell
Measurement of serum 25-hydroxyvitamin D
Analysis of global cognitive efficiency score assessed by the "Montreal Cognitive Assessment" (MoCA).
At risk of falls
patients aged 50 years and over at risk of falls
Measurement of serum 25-hydroxyvitamin D
Analysis of global cognitive efficiency score assessed by the "Montreal Cognitive Assessment" (MoCA).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Measurement of serum 25-hydroxyvitamin D
Analysis of global cognitive efficiency score assessed by the "Montreal Cognitive Assessment" (MoCA).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient able to walk only 15 m, possibly helped by wearing a cane;
* For those aged 50 and over and having fallen: the victim of a fall from a height of uncomplicated fracture in the last 12 months; the fall occurred while standing, or walking, or from the sitting position;
* For those aged 50 and over at risk of falling: woman aged 75 and over, or about having one or more predisposing factors for falls, such as trouble walking or balance (test score the "timed up and got" ≥ 14 sec, muscle weakness of the lower limbs (≤ 4/5), visual disturbance (scale "Monoyer"; corrected visual acuity \<10/20 for the sum of the two eyes), impaired lower limb proprioception (position sense test toes), depression (justifying drug therapy), cognitive disorders (MMS ≤ 26), parkinsonism (known diagnosis and clinical examination), osteoarthritis disrupting travel (known diagnosis and clinical and radiographic examinations), subject taking more than 4 drugs per day, taking psychotropic drugs.
Exclusion Criteria
* The inclusion of the subject in another biomedical research protocol for this study (unless prior approval of the principal investigator);
* The subject can walk only with the help of a third person or with the help of two canes or a walker;
* The subject is suffering from severe or progressive neurological condition;
* The subject has severe cognitive impairment (MMS \<20)
* The subject has significant visual disturbances (corrected visual acuity \<6/20 for the sum of 2 eyes)
* The subject received a "loading dose" of vitamin D in the last 6 months (≥ 100,000 IU);
* For subjects who dropped:
* The fall was caused by a third party (eg stampede);
* The subject has not dropped its height (eg fall from a ladder);
* At the time of the fall, the subject ran or rolled cycling;
* The fall is the result of an accident of the public highway;
* The fall was the cause of a fracture;
* The last drop was more than 12 months.
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Caen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital
Caen, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Christian Marcelli, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-053
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.